Hørsholm,
The grant will support the development of a next-generation influenza vaccine in a large collaboration between public and private R&D organisations from the EU,
ExpreS[2]ion's CEO
"In these unprecedented times we must remember that even the widespread common flu carries an inherent risk of developing into a global pandemic. We appreciate the EU Horizon 2020 grant to work closely within this EU-India-US consortium with the goal to deliver a next-generation flu vaccine that addresses a worldwide medical need."
In addition to ExpreS[2]ion, the INDIGO consortium consists of two Belgian partners, two French partners, two Dutch partners, one US partner, and six Indian partners. See https://cordis.europa.eu/project/id/874653 for more information. The INDIGO consortium's work plan is affected by the current COVID-19 pandemic, which means that initial development work is expected to be deferred by a 4-5 months' time frame from the initial planned starting date of
Influenza
According to WHO (https://www.who.int/news-room/detail/11-03-2019-who-launches-new-global-influenza-strategy), influenza is a serious global health threat that impacts all countries: every year, there are an estimated 1 billion cases, 3-5 million severe cases, and 290 000 - 650 000 influenza-related respiratory deaths worldwide. Serious illness occurs not only in susceptible populations such as paediatrics and older adults, but also in the general population largely because of unique strains of influenza for which most humans have not developed protective antibodies. According to Allied Market Research (https://www.alliedmarketresearch.com/influenza-vaccines-market), the global influenza vaccine market size was valued at 4.0 BUSD in 2018, and is projected to reach 6.2 BUSD by 2026.
Certified Adviser
Telephone: +46 70 755 95 51
E-mail: ca@skmg.se
For further information about ExpreS[2]ion
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
This press release contains information that ExpreS[2]ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on
About ExpreS[2]ion
ExpreS[2]ion
https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-6-7-msek-eu-horizon-2020-grant-for-the-development-of-a-unique-influenza-vaccin,c3077271
https://mb.cision.com/Main/14402/3077271/1221192.pdf
(c) 2020 Cision. All rights reserved., source